A. Alhassan

发表

Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis.

T. Fischmann, K. Maloney, C. Garlisi, 2017, Bioorganic & medicinal chemistry letters.

Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group.

D. Klein, M. Holloway, B. Howell, 2020, ACS medicinal chemistry letters.

Discovery of novel BTK inhibitors with carboxylic acids.

T. Fischmann, K. Maloney, C. Garlisi, 2017, Bioorganic & medicinal chemistry letters.

Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis.

V. Hornak, T. Fischmann, K. Maloney, 2016, ACS medicinal chemistry letters.

Azidonitration of Di-O-acetyl-L-fucal: X-Ray Crystal Structures of Intermediate Azidodeoxysugars and of the Bacterial Aminosugar N-Acetyl-L-fucosamine

M. Zeller, David C. McCutcheon, P. Norris, 2012 .

Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.

T. Fischmann, K. Maloney, C. Garlisi, 2020, Bioorganic & medicinal chemistry letters.

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.

K. Cox, P. Kirschmeier, R. Doll, 2018, ACS medicinal chemistry letters.

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.

P. Kirschmeier, R. Doll, W. Windsor, 2018, Bioorganic & medicinal chemistry letters.

[3+2] Cycloaddition-mediated synthesis of 3-methylsulfanyl-pyrrolidine-3-carboxylic acid methyl ester

R. Doll, A. Cooper, N. Shih, 2009 .

Efficient synthesis of 2H & 13C labeled benzaldehydes via regio-selective formylation

S. B. Boga, D. Hesk, A. Alhassan, 2014 .